Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (91743)	4/5/2000 12:33:00 PM
From: Susan G	Respond to of 120523

The QLGC chart looks really nice (5 minute) and BEAS is gorgeous

To: Jenna who wrote (91743)	4/5/2000 12:52:00 PM
From: bobby is sleepless in seattle	Read Replies (1) \| Respond to of 120523

YHOO...with negative sentiment, tough to trade, first time in recent memory I haven't longed YHOO for earnings run...agreed, better plays...with OJ on the semi's... nice double bottom on ndx at 3960 level, let's see if NDX take out today's high at 4079.. as I've heard somewhere before, we've formed a Pammy Lee intraday

To: Jenna who wrote (91743)	4/5/2000 12:52:00 PM
From: Jenna	Respond to of 120523

SANG is looking for Federal Approval for SangCya capsule version of SangCya (the liquid form) that it will be marketing with Abbott Laboratories, the 'bioequivalent" generic drug for Novartis AG's drug Neoral for transplant patients. Novartis has been trying to block this drug but SANG has always won. If SANG wins approval for this new form of their drug, its market opportunity grows to more than $500 million because capsules are easier to take than liquids and sell better. SANG suffered from the biotech reversal but looks better now. Loses for SANG are shrinking to $1.95 from $2.19. Sales rose 196% to $58 millions and it is expected SANG will turn its first profit in 2001 at $1.16. In addition Abbott invested $14 million in SANG. If SANG wins FDA approval the drug will enjoy the huge sales and marketing possibilities at Abbott's disposal, their huge database of hospitals, doctors, internet bases etc.